Spray Drying as a Fast and Simple Technique for the Preparation of Extended Release Dipyridamole (DYP) Microparticles in a Fixed Dose Combination (FDC) Product with Aspirin

Abstract

Introduction:

Recent advances have proven that the combinational therapy of extended release dipyridamole (DYP) and fast release aspirin (ASP) can improve clinical indices of heart failure in several vascular disorders. Although pharmaceutical industries always supported fast, simple and cost saving techniques in their productions, there is no simple reported method available for this purpose. The aim of this study was to check the possibility of preparing a FDC product, containing individual dosage units of extended release DYP microparticles and fast release ASP, using the spray-drying technique as a practice compatible with pharmaceutical industries.

Materials and Method:

Solid dispersions of DYP in different polymeric substances (ethyl cellulose, carnauba wax, and Eudragit PO 100), were prepared using the spray-drying method. The physicochemical properties and structure of the prepared microparticles were analyzed using different techniques, such as the particle size analyzer (PSA), differential scanning calorimetry (DSC), scanning electron microscopy (SEM), X ray diffraction (XRD), and USP dissolution tester. ASP tablets were prepared individually and tested according to pharmacopeia.

Results and Discussion:

Results showed that prepared microparticles measured about 2.3 µm in size. Statistical analysis of the release data revealed that there is no significant difference in the mean release amount of the selected formulation compared to the innovative brand (Aggrenox^®).

Conclusion:

Findings proposed a new formulation (F7) as an alternative to innovative brand and proved spray drying as a practice compatible with pharmaceutical industries and as a successful method for sustaining the DYP release rate from prepared microparticles in a FDC dosage form.

Key words

Dipyridamole - Spray Drying - Extended Release - Microparticle

• References

• 1 Desai D, Wang J, Wen H et al. Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharmaceutical Development and Technology 2012; 1-12
• 2 Sifton DW. Physicians’ desk reference 2007. Medical Economics Company; 2007
• 3 Verro P, Gorelick PB, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA a meta-analysis. Stroke 2008; 39: 1358-1363
• 4 Halkes PHA, Gray LJ, Bath PMW et al. Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk Journal of Neurology. Neurosurgery & Psychiatry 2008; 79: 1218-1223
• 5 Eicher R. Conference brochure European Conference – Spray Drying – Solutions for the Pharmaceutical Industry. Copenhagen, Denmark 10-11
• 6 Leibovici M, Kanari I, Fox M. Dipyridamole extended-release formulations and process for preparing same. Google Patents, US Patent 20070184110 2007
• 7 Hamishehkar H, Emami J, Najafabadi AR et al. The effect of formulation variables on the characteristics of insulin-loaded poly (lactic-co-glycolic acid) microspheres prepared by a single phase oil in oil solvent evaporation method. Colloids Surf B Biointerfaces 2009; 74: 340-349
• 8 Dobry DE, Settell DM, Baumann JM et al. A model-based methodology for spray-drying process development. Journal of pharmaceutical innovation 2009; 4: 133-142
• 9 FDA. Recommended Dissolution Methods. Available from http://www.accessdata.fda.gov/scripts/cder/dissolution/
• 10 Kaynak MS, Shahin S. A New HPLC Approach for Determination of In-Vitro Solubility of Diprydamole. Hacettepe University J Faculty Pharm 2008; 28: 49-62
• 11 United States Pharmacopoeia . USP XXX: United States Pharmacopoeia Convention. Mack Printing; Rockville: 2007
• 12 Barzegar-Jalali M. Kinetic analysis of drug release from nanoparticles. Journal of Pharmacy & Pharmaceutical Sciences 2008; 11: 167-177
• 13 Valizadeh H, Monajemzadeh F, Nokhoudchi A. Dissolution enhancement of indomethacin by solid dispersions prepared with polyethylene glycoles of different molecular weights. Pharmaceutical Sciences 2005; 65-69
• 14 Clarke EGC. Isolation and identification of drugs in Pharmaceuticals, body fluids, and post-mortem material. Vol 2. The Pharmaceutical Press, 17 Bloomsbury Square; London: WC1A2NN. 2006
• 15 Rowe RC, Sheskey PJ, Owen SC. American Pharmacists A, Library R. Handbook of pharmaceutical excipients. Pharmaceutical press; London: 2003
• 16 Crowley MM, Schroeder B, Fredersdorf A et al. Physicochemical properties and mechanism of drug release from ethyl cellulose matrix tablets prepared by direct compression and hot-melt extrusion. International journal of pharmaceutics 2004; 269: 509-522
• 17 Rama K, Senapati P, Das MK. Formulation and in vitro evaluation of ethyl cellulose microspheres containing zidovudine. Journal of microencapsulation 2005; 22: 863-876
• 18 Gohel MC, Parikh RK, Stavan AN. Spray drying: a review. Pharmainfo net 2009
• 19 Costa P, Jose MSL. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001; 13: 123-133
• 20 Rogovin ZAK. Great Soviet Encyclopedia. 1972; 383-386
• 21 Liu Z, Chung DDL. Burnout of the organic vehicle in an electrically conductive thick-film paste. Journal of electronic materials 2004; 33: 1316-1325